Ropivacaine vs tetracaine in topical anesthesia for intravitreal injection [PDF]
, 2015 Aim: The object of the study was to evaluate the long term efficacy and safety of ropivacaine 0,5% vs tetracaine 0,5% for topical anesthesia in intravitreal injection of dexamethasone in patients with diabetic macular edema (DME) and anti-vascular ...
COLLINI, Saul +6 more
core +1 more source
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model [PDF]
, 2013 Colorectal cancer is the third most commonly diagnosed cancer in the UK after breast and lung cancer. People with metastatic disease who are sufficiently fit are usually treated with active chemotherapy as first- or second-line therapy.
Cooper, Chris +7 more
core +2 more sources
Lycopene inhibits angiogenesis in human umbilical vein endothelial cells and rat aortic rings [PDF]
, 2011 Angiogenesis is important for tumour vascularisation and growth, and is therefore a promising target for cancer therapy. The present study reports inhibition ofin vitroangiogenesis in human umbilical vein endothelial cells (HUVEC) as well as in rat ...
Chopra, Mridula +2 more
core +1 more source
Anti Vascular Endothelial Growth Factor Agents in Corneal Neovascularization
Delhi Journal of Ophthalmology, 2011 Corneal neovascularisation is a potentially blinding condition, an established risk factor for rejection and results in loss of immune privilege. It may occur as a normal physiologic healing response to various stimuli or as an inappropriate local tissue
Srivatsa Sehra, Reetika
doaj +1 more source
Ten years of anti-vascular endothelial growth factor therapy [PDF]
Nature Reviews Drug Discovery, 2016 The targeting of vascular endothelial growth factor A (VEGFA), a crucial regulator of both normal and pathological angiogenesis, has revealed innovative therapeutic approaches in oncology and ophthalmology. The first VEGFA inhibitor, bevacizumab, was approved by the US Food and Drug Administration in 2004 for the first-line treatment of metastatic ...
Ferrara, Napoleone, Adamis, Anthony P
openaire +4 more sources
International Breastfeeding Journal, 2022 Background Ranibizumab is one of intravitreal anti-vascular endothelial growth factor agents. It is applied in the treatments of choroidal neovascularization, age-related macular degeneration, diabetic macular edema, and macular edema secondary to ...
Ying Huang +4 more
doaj +1 more source
Anti-angiogenic therapies for the treatment of angiosarcoma: a clinical update [PDF]
, 2017 Summary: Angiosarcomas are rare aggressive endothelial tumours, and are associated with a poor prognosis. Due to their vascular nature, there is great interest in their response to anti-angiogenic agents.
A Alvarado-Miranda +31 more
core +1 more source
Acta Pharmaceutica, 2022 Statins have shown anti-inflammatory pleiotropic effects in subjects with/at risk of cardiovascular disease. The aim of this study was to evaluate the inflammatory/immunomodulatory properties of rosuvastatin in subjects at low-to-moderate cardiovascular ...
VAVLUKIS ANA +6 more
doaj +1 more source
Anti-vascular endothelial growth factor therapy for malignant glioma [PDF]
Current Neurology and Neuroscience Reports, 2009 Glioblastomas are among the most vascular tumors because they oversecrete vascular endothelial growth factor (VEGF), a potent stimulator of angiogenesis. Consequently, new drug regimens are being developed to target the VEGF signaling pathway in an attempt to halt tumor growth.
Elizabeth R, Gerstner +3 more
openaire +2 more sources
Thromboembolic events in patients treated with anti-angiogenic drugs [PDF]
, 2010 Induction of neo-angiogenesis is a fundamental step in many pathological conditions. The therapeutic value of inhibiting angiogenesis is an interesting area of research in oncology, with vascular endothelial growth factor (VEGF) being the most suitable ...
Ferroni, P +3 more
core +1 more source